Digestive System Neoplasm

In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associat… (full text at CIViC)

PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC

In a retrospective study of 68 irinotecan-refractory metastatic colorectal cancer patients, the tumors of eight patients harbored BRAF V600E but were wildtype for KRAS codons 12, 13, 61 and 146 mutati… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies… (full text at CIViC)

PMID 25989278 · Rowland et al., 2015 · Open in CIViC

In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600… (full text at CIViC)

PMID 22608338 · Falchook et al., 2012 · Open in CIViC

In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy o… (full text at CIViC)

PMID 29431699 · Corcoran et al., 2018 · Open in CIViC

In a phase II trial, 33 patients with advanced or metastatic biliary tract cancer (BTC) received dabrafenib (D) and trametinib (T) in a second or higher line therapeutic context. Of the 33 patients, 3… (full text at CIViC)

Open in CIViC

In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC)

Open in CIViC

Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC)

PMID 28480077 · Kocsis et al., 2017 · Open in CIViC

Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One p… (full text at CIViC)

PMID 28078132 · Lavingia et al., 2016 · Open in CIViC

Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V… (full text at CIViC)

PMID 25435907 · Loaiza-Bonilla et al., 2014 · Open in CIViC

A 78-year-old Chinese female patient presented with BRAF V600E-mutant metastatic pancreatic adenocarcinoma. The patient received two cycles of chemotherapy. Following the second incomplete cycle of ch… (full text at CIViC)

PMID 41367868 · Liu et al., 2025 · Open in CIViC

BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited dura… (full text at CIViC)

PMID 27048246 · Klempner et al., 2016 · Open in CIViC

In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and pho… (full text at CIViC)

PMID 23549875 · Coffee et al., 2013 · Open in CIViC

The results showed that cell lines with BRAF(V600E) or KRAS(G13D) mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they hav… (full text at CIViC)

PMID 25527633 · Huang et al., 2015 · Open in CIViC

665 patients with BRAF V600E-mutated metastatic CRC were enrolled In this open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab… (full text at CIViC)

PMID 31566309 · Kopetz et al., 2019 · Open in CIViC

The open-label phase 3 BEACON CRC trial included 665 patients with BRAF V600E-mutated metastatic CRC. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuxima… (full text at CIViC)

PMID 31566309 · Kopetz et al., 2019 · Open in CIViC

In the randomized phase 3 BREAKWATER trial, previously untreated patients with BRAF V600E-mutated metastatic colorectal cancer receiving first-line encorafenib, cetuximab, and mFOLFOX6 (n=236) had sig… (full text at CIViC)

PMID 40444708 · Elez et al., 2025 · Open in CIViC

The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, … (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than those with wildtype BR… (full text at CIViC)

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC

In this case series, the authors assessed the efficacy and safety of swapping cetuximab for panitumumab as some patients are unable to tolerate treatment with the mouse/human chimeric monoclonal IgG1 … (full text at CIViC)

PMID 35970034 · Rausch et al., 2022 · Open in CIViC

Proteomic analysis of BRAFV600E in melanoma and CRC cell lines revealed a greater sensitivity to combination therapy approach with either PI3K and methyltransferase inhibitors along with PLX4720 (Vemu… (full text at CIViC)

PMID 23251002 · Mao et al., 2013 · Open in CIViC

Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth a… (full text at CIViC)

PMID 23845441 · Rad et al., 2013 · Open in CIViC

In an in vitro study, WiDr, HT-29 and RKO cell lines expressing BRAF V600E mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-typ… (full text at CIViC)

PMID 26865419 · Takigawa et al., 2016 · Open in CIViC

Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC

Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC

In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy o… (full text at CIViC)

PMID 29431699 · Corcoran et al., 2018 · Open in CIViC

In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and… (full text at CIViC)

PMID 26460303 · Kopetz et al., 2015 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 pati… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease … (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Five colorectal cancer (CRC) cell lines (VACO432, HT29, SNU-C5, KM20, WiDr) with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell li… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and thr… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

In an in vitro study, WiDr, HT-29, LS411N, and SW1417 cell lines expressing BRAF V600E and treated with vemurafenib and erlotinib, or vemurafenib and gefitinib were associated with a reduction in cell… (full text at CIViC)

PMID 22448344 · Corcoran et al., 2012 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients tota… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Thirty-two patients with BRAF V600E positive metastatic colorectal cancer (mCRC) and 7 patients with other cancers were treated with a combination of BRAF-inhibitor vemurafenib (960 mg twice daily) an… (full text at CIViC)

PMID 36638198 · Tan et al., 2023 · Open in CIViC

This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

Five colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGF… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified E… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patien… (full text at CIViC)

PMID 25589621 · Yaeger et al., 2015 · Open in CIViC

Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subse… (full text at CIViC)

PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC

A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted,… (full text at CIViC)

PMID 26687137 · Silkin et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC)

PMID 21098728 · Corcoran et al., 2010 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC